Safety and pharmacokinetics of docetaxel in combination with pegvorhyaluronidase alfa in patients with non‐small cell lung cancer. Issue 5 (30th July 2021)

• Record Type: Journal Article
• Authors: Heineman, Thomas; Baumgart, Megan; Nanavati, Charvi; Gabrail, Nash; Van Wart, Scott A.; Mager, Donald E.; Maneval, Daniel C.; Fathallah, Anas M.; Sekulovich, Rose E.
• Is Part Of: Clinical and translational science. Volume 14:Issue 5(2021)
• Page Start: 1875
• Page End: 1885
• Publication Date: 2021-07-30
• Subjects: Medicine, Experimental -- Periodicals; Medical innovations -- Periodicals; 616.027
• DOI: 10.1111/cts.13041
• Languages: English
• ISSNs: 1752-8054

Abstract

Abstract: This open‐label, phase Ib study (NCT02346370) assessed the effect of pegvorhyaluronidase alfa (PVHA; PEGPH20) on the plasma pharmacokinetics (PKs) and safety of docetaxel in 15 patients with stage IIIB/IV non‐small cell lung cancer (NSCLC). The docetaxel PK profile from this study was consistent with simulations from a published docetaxel population PK model, and did not demonstrate an effect of PVHA on docetaxel PK. A maximum a posteriori Bayesian fit of the literature PK model to the docetaxel PK appeared unbiased. Adverse events (AEs) were generally consistent with previous reports for docetaxel monotherapy in NSCLC, except for higher incidence of musculoskeletal events, including myalgias, with PVHA plus docetaxel. The most common AEs were fatigue (87%), muscle spasms (60%), and myalgia (53%). Four patients experienced thromboembolic events (27%), three leading to treatment discontinuation. PVHA appeared to demonstrate an acceptable safety profile when given with docetaxel without significantly changing the plasma PK of docetaxel in patients with stage IIIB/IV NSCLC.